Activating p53 abolishes self-renewal of quiescent leukaemic stem cells in residual CML disease

Scott, M. T. et al. (2024) Activating p53 abolishes self-renewal of quiescent leukaemic stem cells in residual CML disease. Nature Communications, 15, 651. (doi: 10.1038/s41467-024-44771-9) (PMID:38246924) (PMCID:PMC10800356)

[img] Text
316813.pdf - Published Version
Available under License Creative Commons Attribution.

7MB

Abstract

Whilst it is recognised that targeting self-renewal is an effective way to functionally impair the quiescent leukaemic stem cells (LSC) that persist as residual disease in chronic myeloid leukaemia (CML), developing therapeutic strategies to achieve this have proved challenging. We demonstrate that the regulatory programmes of quiescent LSC in chronic phase CML are similar to that of embryonic stem cells, pointing to a role for wild type p53 in LSC self-renewal. In support of this, increasing p53 activity in primitive CML cells using an MDM2 inhibitor in combination with a tyrosine kinase inhibitor resulted in reduced CFC outputs and engraftment potential, followed by loss of multilineage priming potential and LSC exhaustion when combination treatment was discontinued. Our work provides evidence that targeting LSC self-renewal is exploitable in the clinic to irreversibly impair quiescent LSC function in CML residual disease – with the potential to enable more CML patients to discontinue therapy and remain in therapy-free remission.

Item Type:Articles
Additional Information:This study was supported by Blood Cancer UK (Refs. 14033 and 21004; DV, MC), the Stand Up To Cancer campaign for Cancer Research UK (Ref. C55731/A24896; DV, MC), the Howat Foundation (MC), the Glasgow Experimental Cancer Medicine Centre (funded by Cancer Research UK and the Chief Scientist’s Office, Scotland; MC), and Najran University (Saudi Arabia; HA).
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Stevens, Mr Thomas and Dunn, Mrs Karen and Vetrie, Professor David and Almasoudi, Hassan and Scott, Dr Mary and Drotar, Mr Mark and Warren, Felix and Mitchell, Dr Rebecca and Jorgensen, Dr Heather and Pritchard, John and Michie, Professor Alison and Liu, Dr Wei and Kinstrie, Dr Ross and Copland, Professor Mhairi and Clarke, Dr Cassie
Authors: Scott, M. T., Liu, W., Mitchell, R., Clarke, C. J., Kinstrie, R., Warren, F., Almasoudi, H., Stevens, T., Dunn, K., Pritchard, J., Drotar, M. E., Michie, A. M., Jorgensen, H. G., Higgins, B., Copland, M., and Vetrie, D.
College/School:College of Medical Veterinary and Life Sciences
College of Medical Veterinary and Life Sciences > School of Cancer Sciences
Journal Name:Nature Communications
Publisher:Nature Research
ISSN:2041-1723
ISSN (Online):2041-1723
Copyright Holders:Copyright: © The Author(s) 2024
First Published:First published in Nature Communications 15: 651
Publisher Policy:Reproduced under a Creative Commons licence

University Staff: Request a correction | Enlighten Editors: Update this record

Project CodeAward NoProject NamePrincipal InvestigatorFunder's NameFunder RefLead Dept
171051Targeting p53, cMyc and PRC2 regulatory hubs: A systematic and stratified approach to deliver new therapeutics for CMLDavid VetrieBloodwise (BLOODWIS)14033SCS - Paul O'Gorman Leukaemia Research Centre
312473BCUK Programme Continuity GrantDavid VetrieBlood Cancer UK (BLOODCJK)21004SCS - Paul O'Gorman Leukaemia Research Centre
301129TASTER (TArgeting STEm cell Resistance) - Defining leukaemic cell clonal architecture to inform and monitor drug responses in the TASTER CML Phase II Clinical TrialMhairi CoplandCancer Research UK (CRUK)C55731/A24896SCS - Paul O'Gorman Leukaemia Research Centre